TY - JOUR
T1 - Treatment of systemic fungal infections with liposomal amphotericin B
AU - Lopez-Berestein, G.
AU - Bodey, G. P.
AU - Fainstein, V.
AU - Keating, M.
AU - Frankel, L. S.
AU - Zeluff, B.
AU - Gentry, L.
AU - Mehta, K.
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - Forty-six patients with systemic fungal infections were treated with liposomal amphotericin B. Twenty-one patients had disseminated candidiasis, 19 had aspergillosis, and the rest had a variety of other fungal infections. Forty patients failed to respond to conventional amphotericin B therapy, and 6 patients were given liposomal amphotericin B because conventional amphotericin B caused severe side effects. Twenty-four patients had a complete response, and 22 patients failed to respond. No short- or long-term toxic reactions were observed. The acute side effects such as fever, chills, and potassium loss were infrequent and milder than those commonly observed with conventional amphotericin B. No chronic renal, hematologic, or central nervous system side effects were observed. Liposomal amphotericin B therapy was effective and less toxic than conventional amphotericin B therapy.
AB - Forty-six patients with systemic fungal infections were treated with liposomal amphotericin B. Twenty-one patients had disseminated candidiasis, 19 had aspergillosis, and the rest had a variety of other fungal infections. Forty patients failed to respond to conventional amphotericin B therapy, and 6 patients were given liposomal amphotericin B because conventional amphotericin B caused severe side effects. Twenty-four patients had a complete response, and 22 patients failed to respond. No short- or long-term toxic reactions were observed. The acute side effects such as fever, chills, and potassium loss were infrequent and milder than those commonly observed with conventional amphotericin B. No chronic renal, hematologic, or central nervous system side effects were observed. Liposomal amphotericin B therapy was effective and less toxic than conventional amphotericin B therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024468204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024468204&partnerID=8YFLogxK
U2 - 10.1001/archinte.149.11.2533
DO - 10.1001/archinte.149.11.2533
M3 - Article
C2 - 2818111
AN - SCOPUS:0024468204
SN - 0003-9926
VL - 149
SP - 2533
EP - 2536
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 11
ER -